These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34049465)

  • 1. waveRAPID-A Robust Assay for High-Throughput Kinetic Screens with the Creoptix WAVEsystem.
    Kartal Ö; Andres F; Lai MP; Nehme R; Cottier K
    SLAS Discov; 2021 Sep; 26(8):995-1003. PubMed ID: 34049465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Guide to Run Affinity Screens Using Differential Scanning Fluorimetry and Surface Plasmon Resonance Assays.
    Bergsdorf C; Wright SK
    Methods Enzymol; 2018; 610():135-165. PubMed ID: 30390797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hit-to-Lead: Hit Validation and Assessment.
    Hevener KE; Pesavento R; Ren J; Lee H; Ratia K; Johnson ME
    Methods Enzymol; 2018; 610():265-309. PubMed ID: 30390802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of Biophysics in High-Throughput Screening Hit Validation.
    Genick CC; Barlier D; Monna D; Brunner R; Bé C; Scheufler C; Ottl J
    J Biomol Screen; 2014 Jun; 19(5):707-14. PubMed ID: 24695619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C; Ottl J
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPR-based fragment screening: advantages and applications.
    Neumann T; Junker HD; Schmidt K; Sekul R
    Curr Top Med Chem; 2007; 7(16):1630-42. PubMed ID: 17979772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process.
    Danielson UH
    Future Med Chem; 2009 Nov; 1(8):1399-414. PubMed ID: 21426056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
    Giannetti AM
    Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fragment screening using surface plasmon resonance optical biosensor technology].
    Miura T
    Yakugaku Zasshi; 2010 Mar; 130(3):341-8. PubMed ID: 20190519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment screening by SPR and advanced application to GPCRs.
    Shepherd CA; Hopkins AL; Navratilova I
    Prog Biophys Mol Biol; 2014; 116(2-3):113-23. PubMed ID: 25301577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel High-Throughput FLIPR Tetra-Based Method for Capturing Highly Confluent Kinetic Data for Structure-Kinetic Relationship Guided Early Drug Discovery.
    Khurana P; McWilliams L; Wingfield J; Barratt D; Srinivasan B
    SLAS Discov; 2021 Jun; 26(5):684-697. PubMed ID: 33783249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creating a more strategic small molecule biophysical hit characterization workflow.
    Fotsch C; Basu D; Case R; Chen Q; Koneru PC; Lo MC; Ngo R; Sharma P; Vaish A; Yi X; Zech SG; Hodder P
    SLAS Discov; 2024 Jun; 29(4):100159. PubMed ID: 38723666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of inhibitor screening and validation system for tryptophanyl tRNA synthetase using surface plasmon resonance.
    Wang Q; Zhu G; Liu Z
    Anal Biochem; 2021 Jun; 623():114183. PubMed ID: 33798474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biophysics in drug discovery: impact, challenges and opportunities.
    Renaud JP; Chung CW; Danielson UH; Egner U; Hennig M; Hubbard RE; Nar H
    Nat Rev Drug Discov; 2016 Oct; 15(10):679-98. PubMed ID: 27516170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moderate to high throughput in vitro binding kinetics for drug discovery.
    Zhang R; Barbieri CM; Garcia-Calvo M; Myers RW; McLaren D; Kavana M
    Front Biosci (Schol Ed); 2016 Jun; 8(2):278-97. PubMed ID: 27100706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Label free fragment screening using surface plasmon resonance as a tool for fragment finding - analyzing parkin, a difficult CNS target.
    Regnström K; Yan J; Nguyen L; Callaway K; Yang Y; Diep L; Xing W; Adhikari A; Beroza P; Hom RK; Riley B; Rudolph D; Jobling MF; Baker J; Johnston J; Konradi A; Bova MP; Artis DR
    PLoS One; 2013; 8(7):e66879. PubMed ID: 23861750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of RNAi and Small Molecule Screens to Identify Targets for Drug Development.
    Drosopoulos K; Linardopoulos S
    Methods Mol Biol; 2019; 1953():33-42. PubMed ID: 30912014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-impedance-based label-free technology for the identification of new drugs.
    Lundstrom K
    Expert Opin Drug Discov; 2017 Apr; 12(4):335-343. PubMed ID: 28276704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput screening normalized to biological response: application to antiviral drug discovery.
    Patel DA; Patel AC; Nolan WC; Huang G; Romero AG; Charlton N; Agapov E; Zhang Y; Holtzman MJ
    J Biomol Screen; 2014 Jan; 19(1):119-30. PubMed ID: 23860224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.